Home  |  Contact

Cellosaurus MDA-MB-231DR (CVCL_4Z65)

[Text version]

Cell line name MDA-MB-231DR
Accession CVCL_4Z65
Resource Identification Initiative To cite this cell line use: MDA-MB-231DR (RRID:CVCL_4Z65)
Comments Group: Triple negative breast cancer (TNBC) cell line.
Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
Sequence variations Heterozygous for BRAF p.Gly464Val (c.1391G>T) (ClinVar=VCV000040364) (from parent cell line).
Homozygous for CDKN2A deletion (from parent cell line).
Heterozygous for KRAS p.Gly13Asp (c.38G>A) (ClinVar=VCV000012580) (from parent cell line).
TERT c.228C>T (-124C>T); in promoter (from parent cell line).
Homozygous for TP53 p.Arg280Lys (c.839G>A) (ClinVar=VCV000376657) (from parent cell line).
Disease Breast adenocarcinoma (NCIt: C5214)
Derived from metastatic site: Pleural effusion.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0062 (MDA-MB-231)
Sex of cell Female
Age at sampling 51Y
Category Cancer cell line
Publications

PubMed=16928833; DOI=10.1158/1535-7163.MCT-06-0190
Smith L., Watson M.B., O'Kane S.L., Drew P.J., Lind M.J., Cawkwell L.
The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays.
Mol. Cancer Ther. 5:2115-2120(2006)

Cross-references
Other Wikidata; Q54904619
Entry history
Entry creation14-Dec-2015
Last entry update02-Jul-2020
Version number9